✦ LIBER ✦

RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group

✍ Scribed by C.J.A. Punt; M.J.A. de Jonge; S. Monfardini; G. Daugaard; W. Fiedler; B. Baron; D. Lacombe; P. Fumoleau

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epirubicin in previously untreated patie

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 152 KB

Temozolomide in patients with advanced n

✍ R Dziadziuszko; A Ardizzoni; P.E Postmus; E.F Smit; A Price; C Debruyne; C Legra 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Glufosfamide administered by 1-hour infu

✍ G Giaccone; E.F Smit; M de Jonge; E Dansin; E Briasoulis; A Ardizzoni; J.-Y Doui 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Early phase II study of S-1, a new oral

✍ K. Furuse; M. Kawahara; K. Hasegawa; S. Kudoh; M. Takada; T. Sugiura; Y. Ichinos 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 96 KB

Taxotere is active in small cell lung ca

✍ Smyth, JF; Bowman, A; Smith, I; Sessa, C; Kaye, S 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 170 KB

A Phase II Study of the Docetaxel–Carbop

✍ Nicolas Tsavaris; Christos Kosmas; Elias Skopelitis; Kostantinos Gennatas; Alexa 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 111 KB